| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
Mecbotamab vedotin (0.1–10,000 ng/mL) was effective against DU145 cells (EC50 = 16 ng/mL), LCLC-103H cells (EC50 = 37 ng/mL), 293-huAXL (EC50 = 56 ng/mL), and 293-cynoAXL (EC50 = 20 ng/mL) at pH 6.0 [1]. Mecbotamab vedotin (0.01–10,000 ng/mL, 3 days) showed significant cytotoxicity against DU145 cells (IC50 = 1466 ng/mL) and LCLC-103H cells (IC50 = 474 ng/mL) at pH 6.0, but was nontoxic to 293-F cells [1].
|
|---|---|
| ln Vivo |
Mecbotamab vedotin (1-6 mg/kg, intravenously, once every 4 days for a total of 6 times) significantly inhibited tumor growth in female NOD/SCID mice bearing LCLC-103H tumors[1]. Mecbotamab vedotin (1-10 mg/kg, intravenously, once every 4 days for a total of 4 times) significantly inhibited tumor growth in female NOD/SCID mice bearing MIA PaCa-2 tumors[1]. Mecbotamab vedotin (6-15 mg/kg, intravenously, once every 4 days for a total of 6 times) significantly delayed tumor growth in male BALB/c nude mice bearing DU145 tumors[1].
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: DU145 cells, LCLC-103H cells and 293-F cells Tested Concentrations: 0.01-10000 ng/mL Incubation Duration: 3 days Experimental Results: At pH 6.0, it significantly killed DU145 cells (IC50 = 1466 ng/mL) and LCLC-103H cells (IC50 = 474 ng/mL). At pH 7.4, it effectively killed DU145 cells (IC50 = 5069 ng/mL) and LCLC-103H cells (IC50 = 1095 ng/mL). There was no significant toxicity to 293-F cells. |
| Animal Protocol |
Animal/Disease Models:Female NOD/SCID mice were injected with 1×10⁶ LCLC-103H cells[1]
Doses: 1, 3 and 6 mg/kg Route of Administration: Intravenous (iv) every 4 days for a total of 6 times Experimental Results: Significantly inhibited tumor growth (TGI range of 114-115%), with efficacy lasting up to 57 days in the 3 mg/kg and 6 mg/kg groups. Animal/Disease Models:Female NOD/SCID mice were injected with 1×10⁶ MIA PaCa-2 cells[1] Doses: 1, 3, 6 and 10 mg/kg Route of Administration: Intravenous (iv) once every 4 days for a total of 4 times Experimental Results: The tumor growth inhibition rate (TGI) in the 6 mg/kg group was 59%, and the tumors in the 10 mg/kg group completely regressed. Animal/Disease Models:Female NOD/SCID mice were injected with 5 × 10⁶ DU145 cells [1] Doses: 6, 10 and 15 mg/kg Route of Administration: Intravenous (iv) every 4 days for a total of 6 times Experimental Results: Sustained antitumor activity was observed in the 10 and 15 mg/kg groups. |
| References |
| CAS # |
2460400-64-8
|
|---|---|
| Appearance |
Colorless to light yellow liquid
|
| SMILES |
[Mecbotamab vedotin]
|
| Synonyms |
BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 本产品在运输和储存过程中需避光（避免光照）。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
